Please login to the form below

Not currently logged in
Email:
Password:

NICE rejects three bowel cancer drugs

The National Institute for Health and Clinical Excellence (NICE) has decided to not recommend three metastatic colorectal cancer drugs as they are not deemed cost effective

The National Institute for Health and Clinical Excellence (NICE) has rejected three drugs for the treatment of metastatic colorectal cancer, as they do not represent value for money.

NICE decided not to recommend Roche's Avastin, Merck KGaA's Erbitux and Amgen's Vectibix, as the high cost of the drugs could not be justified. The agency said that no convincing data was presented to demonstrate the extension of life for a patient with the disease.

NICE has currently recommended six treatments for the various stages of colorectal cancer, and commented that it was “disappointed not to be able to recommend” the three drugs.

Around 20-55 per cent of people with colorectal cancer have metastatic disease by the time of diagnosis.

The companies have been allowed to submit further comments on the committee's interpretation of their products, or consider reducing their prices.

5th September 2011

From: Healthcare

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Dovetail

We're award-winning joint working specialists. We help our clients to transform healthcare through effective collaboration, and deliver work to feel...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics